Kingstone Capital Partners Texas LLC Makes New Investment in Solventum Corporation $SOLV

Key Points

• Kingstone Capital Partners Texas LLC acquired 172,848 shares of Solventum Corporation, valued at approximately $13.1 million, representing a 0.10% ownership stake in the company as of the latest reporting period.
• Solventum reported a 12-month revenue increase of 3.8% year-over-year, achieving $2.16 billion in revenue for the quarter and an EPS of $1.69, exceeding analysts' expectations.
• The company's stock has received mixed ratings from analysts, with a consensus target price of $85.44 and one analyst rating it as a Strong Buy.

Kingstone Capital Partners Texas LLC bought a new position in Solventum Corporation (NYSE:SOLV - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 172,848 shares of the company's stock, valued at approximately $13,109,000. Kingstone Capital Partners Texas LLC owned approximately 0.10% of Solventum as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in SOLV. Rossby Financial LCC bought a new position in shares of Solventum in the 1st quarter worth approximately $25,000. Strengthening Families & Communities LLC increased its position in Solventum by 376.8% during the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company's stock valued at $25,000 after buying an additional 260 shares in the last quarter. Hara Capital LLC bought a new position in Solventum during the 1st quarter valued at approximately $38,000. Smartleaf Asset Management LLC increased its position in Solventum by 193.4% during the 1st quarter. Smartleaf Asset Management LLC now owns 534 shares of the company's stock valued at $40,000 after buying an additional 352 shares in the last quarter. Finally, Costello Asset Management INC bought a new stake in shares of Solventum in the 1st quarter worth $42,000.

Solventum Price Performance

Shares of NYSE:SOLV traded up $0.04 during mid-day trading on Tuesday, reaching $73.80. The stock had a trading volume of 222,265 shares, compared to its average volume of 1,085,216. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. The company has a market cap of $12.80 billion, a P/E ratio of 34.16, a price-to-earnings-growth ratio of 3.00 and a beta of 0.53. Solventum Corporation has a 1 year low of $60.70 and a 1 year high of $85.92. The business's 50 day moving average price is $72.97 and its 200 day moving average price is $72.32.

Solventum (NYSE:SOLV - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping analysts' consensus estimates of $1.45 by $0.24. The company had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.12 billion. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The firm's revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the previous year, the business earned $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Research analysts expect that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on SOLV. Zacks Research raised Solventum from a "hold" rating to a "strong-buy" rating in a report on Monday, September 15th. Piper Sandler reaffirmed an "overweight" rating and issued a $94.00 price objective (up previously from $87.00) on shares of Solventum in a report on Friday, August 8th. KeyCorp initiated coverage on Solventum in a research report on Friday, June 6th. They set a "sector weight" rating on the stock. Morgan Stanley upgraded Solventum from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. Finally, Argus upgraded Solventum from a "hold" rating to a "buy" rating and set a $90.00 target price on the stock in a research report on Tuesday, July 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $85.44.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.